Portal de Periódicos da CAPES

Recalcitrant pyoderma gangrenosum: Treatment with thalidomide

1998; Elsevier BV; Volume: 38; Issue: 3 Linguagem: Inglês

10.1016/s0190-9622(98)70513-4

1097-6787

Melanie S. Hecker, Mark Lebwohl,

Chronic Lymphocytic Leukemia Research

Thalidomide, a derivative of glutamic acid, was first introduced to the German market as Contergan in 1956.1 The drug was then marketed in England and eventually to the rest of the world after 1958.2 However, the drug did not enter the American market. It was prescribed as a sedative-hypnotic and an antiemetic for women in the first trimester of pregnancy.3 With the subsequent reports of peripheral neuropathy4 and infant limb defects,1 thalidomide was withdrawn from the world market. In 1965, thalidomide's dramatic effects on erythema nodosum leprosum were observed.